Alex Berenson puts the case that the Covid vaxxes never have stopped hospitalisations, or death, even at peak effectiveness.  He shows that a US database, used in an article published online December 28 in the Journal of the American Medical Association - JAMA Internal Medicine, offers proof. Vaccinated people had a nearly 1 in 200 probability of requiring hospitalization for Covid in the first six months after being “fully vaccinated.” Deaths, ventilator use, and other severe outcomes also occurred in vaccinated people.

https://alexberenson.substack.com/p/vaccines-dont-stop-covid-hospitalizations?fbclid=IwAR0nUJ4btxHpGsaqN1V5JGUHeojklLANLuCrd3-FK7UmxxMPzxHd6mbx7KQ

“Even at the peak of their protection earlier in 2021, Covid vaccines barely reduced the risk of hospitalizations in vaccinated people who had “breakthrough” infections, new data show.

Vaccinated people in a study published Tuesday had a nearly 1 in 200 chance of of requiring hospitalization for Covid in the first six months after being “fully vaccinated.”

That stunning risk came even though the median age of people in the study was only 51, and most were relatively healthy.

Deaths, ventilator use, and other severe outcomes also occurred regularly in vaccinated people. The data comes from a study of about 600,000 vaccinated Americans seen at over 100 academic medical centers.

The study was published online Dec. 28 in the Journal of the American Medical Association - JAMA Internal Medicine.

The data in the study also make clear how quickly vaccine protection fades after the second dose - and that the Centers for Disease Control hugely understated the number of vaccinated people hospitalized for Covid earlier this year.

Of the 600,000 fully vaccinated people, about 2,800 required inpatient hospitalization for Covid in the first six months after “full vaccination.” That period starts 14 days after the second dose of mRNA vaccines, when vaccine protection should be at peak.

Almost 3 percent of fully vaccinated people, or 1 in 35, were infected over the first six months, with infection rates accelerating sharply at the end of the study.

In all, 148 of the 600,000 vaccinated people had what the study’s authors called “serious” outcomes from Covid, including ventilation or death, in the first six months after full vaccination.

The study does not reveal how many people were infected or hospitalized for Covid after the first dose or less than two weeks after the second, when rates of infection, hospitalization, and death are known to be even higher.

The stunning figures are buried in a supplemental table of the study, which focused on the post-vaccination risk to a small group of people who have serious immune complications. The paper’s researchers compared infection, hospitalization, and death rates in about 35,000 immune-compromised people with about 570,000 who did not.

Somewhat surprisingly, the researchers found immune-compromised people had only a slight extra risk of SARS-Cov-2 infection, though they had about three times the risk of dying from Covid as people without immune disorders.

But by far the most interesting figures in the study are contained in a single small table in an appendix.

It compares the outcomes of the roughly 18,000 vaccinated and infected people seem at the medical centers with a much larger group of Covid patients - about 2.5 million people - who were not vaccinated and visited the same centers at any point during the epidemic.

About 84 percent of the vaccinated patients were seen as outpatients, while 16 percent required hospitalization.

In comparison, about 77 percent of unvaccinated patients were seen as outpatients, while 23 percent were hospitalized.

Almost 1 percent of the vaccinated patients had serious outcomes, including death, compared to just over 2 percent of the unvaccinated patients.

The study contained no information about post-vaccine side effects.

The findings run contrary to the endlessly repeated promises of Covid vaccine advocates that even if vaccines fail to prevent infection, they are necessary to keep hospitals from being overrun. They also help bring American hospitalization data - which is both fragmented and hopelessly politicized in a desperate effort to prove vaccine efficacy - more in line with figures from the United Kingdom and other countries.

SOURCE: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2787643?guestAccessKey=356d5298-a97b-47ea-8db3-99dc9e039a6e&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamainternalmedicine&utm_content=olf&utm_term=122821

Original Investigation

December 28, 2021

Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US

Jing Sun, MD, MPH, PhD¹; Qulu Zheng, MS¹; Vithal Madhira, MS²; et al Amy L. Olex, MS³; Alfred J. Anzalone, MS⁴; Amanda Vinson, MD⁵; Jasvinder A. Singh, MD^6,7; Evan French, BS³; Alison G. Abraham, PhD⁸; Jomol Mathew, PhD⁹; Nasia Safdar, MD, PhD¹⁰; Gaurav Agarwal, MD, MSPH¹¹; Kathryn C. Fitzgerald, ScD^1,12; Namrata Singh, MD¹³; Umit Topaloglu, PhD¹⁴; Christopher G. Chute, MD, DrPH, MPH^1,15; Roslyn B. Mannon, MD¹⁶; Gregory D. Kirk, MD, MPH, PhD^1,17; Rena C. Patel, MD, MPH¹⁸; for the National COVID Cohort Collaborative (N3C) Consortium

Author Affiliations Article Information

JAMA Intern Med. Published online December 28, 2021. doi:10.1001/jamainternmed.2021.7024

Key Points

Question  Is immune dysfunction associated with an increased risk for COVID-19 breakthrough infection after SARS-CoV-2 vaccination?

Findings  In this cohort study of 664 722 patients who received at least 1 dose of a SARS-CoV-2 vaccine, those with immune dysfunction, such as HIV infection, rheumatoid arthritis, and solid organ transplant, had a higher rate for COVID-19 breakthrough infection and worse outcomes after full or partial vaccination, compared with persons without immune dysfunction.

Meaning  The findings suggest that persons with immune dysfunction are at much higher risk for contracting a breakthrough infection and thus should use nonpharmaceutical interventions (eg, mask wearing) and alternative vaccination approaches (eg, additional dose or immunogenicity testing) even after full vaccination.

Abstract

Importance  Persons with immune dysfunction have a higher risk for severe COVID-19 outcomes. However, these patients were largely excluded from SARS-CoV-2 vaccine clinical trials, creating a large evidence gap.

Objective  To identify the incidence rate and incidence rate ratio (IRR) for COVID-19 breakthrough infection after SARS-CoV-2 vaccination among persons with or without immune dysfunction.

Design, Setting, and Participants  This retrospective cohort study analyzed data from the National COVID Cohort Collaborative (N3C), a partnership that developed a secure, centralized electronic medical record–based repository of COVID-19 clinical data from academic medical centers across the US. Persons who received at least 1 dose of a SARS-CoV-2 vaccine between December 10, 2020, and September 16, 2021, were included in the sample.

Main Outcomes and Measures  Vaccination, COVID-19 diagnosis, immune dysfunction diagnoses (ie, HIV infection, multiple sclerosis, rheumatoid arthritis, solid organ transplant, and bone marrow transplantation), other comorbid conditions, and demographic data were accessed through the N3C Data Enclave. Breakthrough infection was defined as a COVID-19 infection that was contracted on or after the 14th day of vaccination, and the risk after full or partial vaccination was assessed for patients with or without immune dysfunction using Poisson regression with robust SEs. Poisson regression models were controlled for a study period (before or after [pre– or post–Delta variant] June 20, 2021), full vaccination status, COVID-19 infection before vaccination, demographic characteristics, geographic location, and comorbidity burden.

Results  A total of 664 722 patients in the N3C sample were included. These patients had a median (IQR) age of 51 (34-66) years and were predominantly women (n = 378 307 [56.9%]). Overall, the incidence rate for COVID-19 breakthrough infection was 5.0 per 1000 person-months among fully vaccinated persons but was higher after the Delta variant became the dominant SARS-CoV-2 strain (incidence rate before vs after June 20, 2021, 2.2 [95% CI, 2.2-2.2] vs 7.3 [95% CI, 7.3-7.4] per 1000 person-months). Compared with partial vaccination, full vaccination was associated with a 28% reduced risk for breakthrough infection (adjusted IRR [AIRR], 0.72; 95% CI, 0.68-0.76). People with a breakthrough infection after full vaccination were more likely to be older and women. People with HIV infection (AIRR, 1.33; 95% CI, 1.18-1.49), rheumatoid arthritis (AIRR, 1.20; 95% CI, 1.09-1.32), and solid organ transplant (AIRR, 2.16; 95% CI, 1.96-2.38) had a higher rate of breakthrough infection.

Conclusions and Relevance  This cohort study found that full vaccination was associated with reduced risk of COVID-19 breakthrough infection, regardless of the immune status of patients. Despite full vaccination, persons with immune dysfunction had substantially higher risk for COVID-19 breakthrough infection than those without such a condition. For persons with immune dysfunction, continued use of nonpharmaceutical interventions (eg, mask wearing) and alternative vaccine strategies (eg, additional doses or immunogenicity testing) are recommended even after full vaccination.”